Typically, the evaluation of RAS and BRAF mutational status requires the acquisition of tumor tissue, the subsequent processing to formalin-fixed paraffin-embedded (FFPE) specimens, and molecular testing with various techniques, with consequent limitations in studying a single snapshot of a tumor due to both tumor heterogeneity and treatment associated evolution. The gene discussed is BRAF; the disease is neoplasm.